Mobilized PBPC concentrates: A maturing blood component

Transfusion

Volumn 41, Issue 2, 2001, Pages 168-171

  Stroncek, David ^a,b   Anderlini, Paolo ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CD34 ANTIGEN; IFOSFAMIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

APHERESIS; CELL ADHESION; EDITORIAL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL;

CELL AGING; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; STEM CELLS;

EID: 0035106970     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41020168.x     Document Type: Editorial

References (30)

1. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
2. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
3. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
4. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
5. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
6. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies
7. Nonmyeloablative, T-cell depleted allogeneic peripheral blood stem cell (PBSC) transplantation for patients with chronic granulomatous disease
8. Donor age-related differences in PBPC mobilization with rHuG-CSF
9. CD34+ cell mobilization for allogeneic progenitor cell transplantation: Efficacy of a short course of G-CSF
10. PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: Results of a prospective randomized trial
11. Cytokine and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization
12. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs
13. Large volume leukapheresis maximizes the progenitor cell yield for allogeneic peripheral blood progenitor donation
14. Kinetics of peripheral blood stem cell harvests during a single apheresis
15. Clinical and laboratory evaluation of citrate effects and calcium replacement therapy in large volume leukapheresis (LVL)
16. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors
17. Prevention and management of mucositis in patients with cancer
18. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation
19. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
20. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma
21. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells
22. Spontaneous rupture of the spleen during peripheral blood stem-cell mobilisation in a healthy donor
23. Hematopoietic growth factors for the treatment of severe chronic neutropenia
24. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patient with severe congenital neutropenias
25. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor
26. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor
27. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity
28. Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor
29. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor
30. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: The MD Anderson Cancer Center experience